Moderna Faces Sales Slump: Can New mRNA Products Revive Growth by 2025?

Moderna (NASDAQ: MRNA) has set its sights on an impressive sales forecast for 2025, projecting revenue between $2.5 billion and $3.5 billion. This projection comes on the heels of the company's lower-than-expected sales estimates for this year, which are anticipated to ring in at around $3 billion to $3.5 billion—the company's weakest performance since it released its COVID-19 vaccine in late 2020.

Stephen Mock, Moderna's Chief Financial Officer, hinted at a cautious optimism regarding the revenue outlook. He emphasized the unpredictability surrounding the COVID-19 and the respiratory syncytial virus (RSV) markets. The company expects that by 2026 to 2028, new product rollouts could inspire an average annual revenue growth rate of 25%. However, for the immediate future, Mock cautioned that while some new product approvals may occur in 2025, the monetary contributions from these launches would remain limited.

The dilemma for Moderna lies in its transition from the lucrative COVID vaccine market to other mRNA-based offerings. The firm is banking on new entries, particularly its RSV vaccine, dubbed mRESVIA, to offset dwindling revenues from pandemic-related shots that boomed in 2020 and 2021. This year, Moderna plans to seek FDA approval to broaden mRESVIA's availability to high-risk adults under 60, following promising results from its late-stage trials.

Despite the challenges, anticipation surrounds Moderna's new product pipeline. The company is looking to introduce ten new products by 2027, with the hope that significant revenue generation will begin by 2028. However, traders may find it worth noting that the immediate revenue impact from these forthcoming products may not be substantial.

In the light of these developments, shares of Moderna took a hit of around 7%, trading at $73.94 during premarket hours. As analysts predict revenues of $3.27 billion for 2024 and $3.74 billion for 2025, investors may want to closely monitor how Moderna navigates this tricky transition period.